# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")))), a clinical-stage biopharmaceutical Company developing ...
HC Wainwright & Co. analyst Matthew Caufield maintains Opthea (NASDAQ:OPT) with a Buy and lowers the price target from $...
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence ...
Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual out...